Quigley Pharma Announces Continued Progress In Natural Broad Spectrum Anti-Viral For Use In Preventing Spread Of Avian Flu In Poultry Stocks

Quigley Pharma, a
wholly-owned subsidiary of The Quigley Corporation (Nasdaq: QGLY),
announced today that it has obtained positive results that support Quigley
Pharma's continued progress in developing the natural broad spectrum
anti-viral QR-441(a) for use in preventing the spread of avian flu in
poultry stocks. The results of the healthy chicken medical feed study
confirm that food or water dose forms provide an opportunity for potential
commercialization if the compound demonstrates efficacy within these dose
forms.


The results clearly showed that the chickens tolerated and consumed all
concentrations of QR-441(a) in the medicated feed. They also tolerated and
consumed the low concentration of drug in the medicated water. Dr. Timothy
Cummings, MS DVM, ACPV, Clinical Poultry Professor, College of Veterinary
Medicine, Mississippi State University conducted the trial.


The Company is preparing to test QR-441(a) in chickens infected with
H5N1 in challenge studies. These studies will center on the well-tolerated
medicated food and water although other dose forms or delivery systems may
be considered. To that end, the Company has developed challenge study
protocols and has entered into preliminary agreements with several
international research facilities that are qualified to conduct challenge
testing with such highly infective pathogens. These proposed studies are in
support of a previously assigned FDA INAD No. 011427 that allows Quigley
Pharma to conduct further in-vivo chicken challenge studies.


"Follow up efficacy challenge studies will be conducted internationally
for two reasons, primarily due to the fact that there are few domestic
facilities willing to conduct chicken challenge studies with this highly
infective pathogen, and secondly, to facilitate the broadest possible
distribution in the event of positive results and an eventual outbreak,"
stated Dr. Richard Rosenbloom, COO, Quigley Pharma.


Should an outbreak of H5N1 occur in the United States, the federal and
local government, working in conjunction with the poultry industry, will
likely establish a hot zone where all poultry will be slaughtered.
Immediately outside the hot zone will be a buffer zone perimeter in which
poultry will be at a greater risk of infection by H5N1 than those further
outside the hot zone. QR-441(a) is designed specifically for use in the
buffer zone perimeter.


The Quigley Corporation makes no representation that the U.S. Food and
Drug Administration or any other regulatory agency will allow the
aforementioned Investigational New Drug to be marketed. Furthermore, no
claim is made that the potential medicine discussed here is safe,
effective, or approved by the Food and Drug Administration.


About The Quigley Corporation


The Quigley Corporation (Nasdaq: QGLY, Quigleyco) is a
diversified natural health medical science company. Its Cold Remedy segment
is a leading marketer and manufacturer of the COLD-EEZE(R) family of
lozenges, gums and sugar free tablets clinically proven to cut the common
cold nearly in half. COLD-EEZE customers include leading national
wholesalers and distributors, as well as independent and chain food, drug
and mass merchandise stores and pharmacies. The Quigley Corporation has
several wholly owned subsidiaries. Darius International markets health and
wellness products through its wholly owned subsidiary, InnerLight Inc.
Quigley Manufacturing Inc. consists of two FDA approved facilities to
manufacture COLD-EEZE(R) lozenges as well as fulfill other contract
manufacturing opportunities. Quigley Pharma Inc.


(QuigleyPharma) conducts research in order to develop and
commercialize a pipeline of patented botanical and naturally derived
prescription drugs.


Certain statements in this press release are "forward-looking
statements" within the meaning of the Private Securities Litigation Reform
Act of 1995 and involve known and unknown risk, uncertainties and other
factors that may cause the company's actual performance or achievements to
be materially different from the results, performance or achievements
expressed or implied by the forward-looking statement. Factors that impact
such forward-looking statements include, among others, changes in worldwide
general economic conditions, changes in interest rates, government
regulations, and worldwide competition.



The Quigley Corporation

QuigleyPharma